UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fulvestrant in management of hormone receptor-positive metastatic breast cancer

Future oncology (London, England), 2018-08, Vol.14 (18), p.1789-1800

2018

Volltextzugriff (PDF)

Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers

Breast cancer research and treatment, 2022-11, Vol.196 (1), p.143-152

2022

Volltextzugriff (PDF)

Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases

Current problems in cancer. Case reports, 2020-12, Vol.2, p.100034, Article 100034

2020

Volltextzugriff (PDF)

Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps

JNCI : Journal of the National Cancer Institute, 2017-07, Vol.109 (7)

2017

Volltextzugriff (PDF)

Evaluating factors contributing to low rates of breast cancer clinical trial accrual in a diverse patient population

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.100-100

2022

Volltextzugriff (PDF)

Risk reducing surgeries among mutation carriers treated at a safety NET hopsital breast cancer clinic

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e12583-e12583

2022

Volltextzugriff (PDF)

Evaluating patient risk factors associated with low rates of breast cancer clinical trial accrual

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18547-e18547

2022

Volltextzugriff (PDF)

Editorial: Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps

JNCI : Journal of the National Cancer Institute, 2017-07, Vol.109 (7)

2017

Volltextzugriff (PDF)

Abstract P33: Disparities in breast cancer screening and the impact of COVID-19 in Houston, Texas

Clinical cancer research, 2021-03, Vol.27 (6_Supplement), p.P33-P33

2021

Volltextzugriff (PDF)

National claims data analysis of outcomes of hospitalized cancer patients without COVID-19 infection during versus prior to the COVID-19 pandemic

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18679-e18679

2022

Volltextzugriff (PDF)

Abstract OT2-28-01: A phase 2 study of sitravatinib in metastatic, pre-treated, triple negative breast cancer, NCT # 04123704

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-28-01-OT2-28-01

2022

Volltextzugriff (PDF)

Rising Obesity and Breast Cancer Screening

Juniper online journal of public health, 2018-05, Vol.3 (4)

Maryam, Nemati Shafaee

2018

Volltextzugriff (PDF)

Abstract P2-09-09: Genetic assessment of hereditary breast and ovarian cancer in the Smith Clinic: A 10-year, single center experience

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-09-09

2022

Volltextzugriff (PDF)

Change in management based on actionable mutations in metastatic breast cancer in an ethnically diverse cohort: Single institution experience

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e13067-e13067

2021

Volltextzugriff (PDF)

Patient education intervention to improve diversity in breast cancer clinical trials

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.104-104

2022

Volltextzugriff (PDF)

Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer

Cancer cell, 2020-03, Vol.37 (3), p.387-402.e7

2020

Volltextzugriff (PDF)

Concurrent Chemo-radiation As a Means of Achieving Pathologic Complete Response in Triple Negative Breast Cancer

Clinical breast cancer, 2022-06, Vol.22 (4), p.e536-e543

2022

Volltextzugriff (PDF)

Patient education intervention to improve breast cancer clinical trials participation

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18532-e18532

2022

Volltextzugriff (PDF)

Abstract P5-14-02: Breast cancer clinical trial participation rate among patients of low socioeconomic status at a comprehensive cancer center

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-14-02

2022

Volltextzugriff (PDF)

Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil

The oncologist (Dayton, Ohio), 2022-05, Vol.27 (5), p.344-351

2022

Volltextzugriff (PDF)

Oncotype Dx analysis in early stage breast cancer (BC) in BRCA mutation carriers versus non-carriers

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e12065-e12065

2016

Volltextzugriff (PDF)

Aromatase inhibitors and the risk of contralateral breast cancer in BRCA mutation carriers

Journal of clinical oncology, 2015-10, Vol.33 (28_suppl), p.3-3

2015

Volltextzugriff (PDF)

Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer

Chinese Clinical Oncology, 2018-06, Vol.7 (3), p.25-25

2018

Volltextzugriff (PDF)

Abstract P4-03-25: Patient-level predictors of skipping screening mammograms during the COVID-19 pandemic at a large tertiary care center in Texas

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P4-P4-03-25

2023

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fulvestrant in management of hormone receptor-positive metastatic breast cancer

Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases

Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps

Evaluating factors contributing to low rates of breast cancer clinical trial accrual in a diverse patient population

Risk reducing surgeries among mutation carriers treated at a safety NET hopsital breast cancer clinic

Evaluating patient risk factors associated with low rates of breast cancer clinical trial accrual

Editorial: Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps

Abstract P33: Disparities in breast cancer screening and the impact of COVID-19 in Houston, Texas

National claims data analysis of outcomes of hospitalized cancer patients without COVID-19 infection during versus prior to the COVID-19 pandemic

Abstract OT2-28-01: A phase 2 study of sitravatinib in metastatic, pre-treated, triple negative breast cancer, NCT # 04123704

Rising Obesity and Breast Cancer Screening

Abstract P2-09-09: Genetic assessment of hereditary breast and ovarian cancer in the Smith Clinic: A 10-year, single center experience

Change in management based on actionable mutations in metastatic breast cancer in an ethnically diverse cohort: Single institution experience

Patient education intervention to improve diversity in breast cancer clinical trials

Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer

Concurrent Chemo-radiation As a Means of Achieving Pathologic Complete Response in Triple Negative Breast Cancer

Patient education intervention to improve breast cancer clinical trials participation

Abstract P5-14-02: Breast cancer clinical trial participation rate among patients of low socioeconomic status at a comprehensive cancer center

Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil

Oncotype Dx analysis in early stage breast cancer (BC) in BRCA mutation carriers versus non-carriers

Aromatase inhibitors and the risk of contralateral breast cancer in BRCA mutation carriers

Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer

Abstract P4-03-25: Patient-level predictors of skipping screening mammograms during the COVID-19 pandemic at a large tertiary care center in Texas

Suchergebnisse filtern